2016 comprehensive update of the Banff working group on liver allograft pathology: Introduction of antibody-mediated rejection

American Journal of Transplantation

Volumn 16, Issue 10, 2016, Pages 2816-2835

  Demetris, A Jake ^a   Bellamy, C ^b   Hubscher S G ^c   O'Leary J ^d   Randhawa, P S ^a   Feng, S ^e   Neil, D ^f   Colvin, R B ^g   McCaughan, G ^h   Fung, J J ⁱ   Del Bello, A ^j   Reinholt, F P ^k   Haga, H ^l   Adeyi, O ^m   Czaja, A J ⁿ   Schiano, T ^o   Fiel, M I ^p   Smith, M L ^q   Sebagh, M ^r   Tanigawa, R Y ^s   Yilmaz, F ^t   Alexander, G ^u   Baiocchi, L ^v   Balasubramanian, M ^w   Batal, I ^x   Bhan, A K ^g   Bucuvalas, J ^y   Cerski, C T S ^z   Charlotte, F ^aa   De Vera, M E ^ab   Elmonayeri, M ^ac   Fontes, P ^a   Furth, E E ^ad   Gouw, A S H ^ae   Hafezi Bakhtiari, S ^af   Hart, J ^ag   Honsova, E ^ah   Ismail, W ^ai   Itoh, T ^aj   Jhala, N C ^ak   Khettry, U ^al   Klintmalm, G B ^d   Knechtle, S ^am   Koshiba, T ^an   Kozlowski, T ^ao   Lassman, C R ^ap   Lerut, J ^aq   Levitsky, J ^ar   Licini, L ^as   Liotta, R ^at   Mazariegos, G ^au   Minervini, M I ^a   Misdraji, J ^g   Mohanakumar, T ^av   Molne J ^aw   Nasser, I ^ax   Neuberger, J ^f   O'Neil M ^ay   Pappo, O ^az   Petrovic, L ^ba   Ruiz, P ^bb   Sagol O ^bc   Sanchez Fueyo, A ^bd   Sasatomi, E ^be   Shaked, A ^bf   Shiller, M ^d   Shimizu, T ^bg   Sis, B ^bh   Sonzogni, A ^as   Stevenson, H L ^bi   Thung, S N ^p   Tisone, G ^bj   Tsamandas, A C ^bk   Wernerson, A ^bl   Wu, T ^bm   Zeevi, A ^bn   Zen, Y ^aj   more..

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j CHU RANGUEIL   (France)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l KYOTO UNIVERSITY HOSPITAL   (Japan)

^m UNIVERSITY HEALTH NETWORK   (Canada)

ⁿ Mayo Clinic College of Medicine   (United States)

^o MOUNT SINAI MEDICAL CENTER   (United States)

^p MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^q MAYO CLINIC   (United States)

^r HÔPITAL PAUL BROUSSE   (France)

^s UNIVERSITY OF SÃO PAULO   (Brazil)

^t EGE UNIVERSITY   (Turkey)

^u UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^v TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^w EINSTEIN MEDICAL CENTER   (United States)

^x Columbia University College of Physicians and Surgeons ^*  (United States)

^y CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^z HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^aa PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^ab LOMA LINDA UNIVERSITY   (United States)

^ac AIN SHAMS UNIVERSITY   (Egypt)

^ad HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^ae UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^af TORONTO GENERAL HOSPITAL   (Canada)

^ag UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^ah INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^ai BENI SUEF UNIVERSITY   (Egypt)

^aj KOBE UNIVERSITY HOSPITAL   (Japan)

^ak TEMPLE UNIVERSITY   (United States)

^al LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^am DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^an Soma Central Hospital   (Japan)

^ao UNIVERSITY OF NORTH CAROLINA   (United States)

^ap UNIVERSITY OF CALIFORNIA   (United States)

^aq CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^ar NORTHWESTERN UNIVERSITY   (United States)

^as Pope John XXIII Hospital   (Italy)

^at MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^au CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^av ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^aw SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^ax BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^ay UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^az HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^ba UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^bb UNIVERSITY OF MIAMI   (United States)

^bc DOKUZ EYLUL UNIVERSITY   (Turkey)

^bd KING S COLLEGE HOSPITAL   (United Kingdom)

^be UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^bf UNIVERSITY OF PENNSYLVANIA   (United States)

^bg Toda Chuo General Hospital   (Japan)

^bh UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^bi UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^bj UNIVERSITY OF ROME TOR VERGATA   (Italy)

^bk UNIVERSITY OF PATRAS   (Greece)

^bl KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^bm TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bn UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4D; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; RITUXIMAB; ALLOANTIBODY;

ANTIBODY MEDIATED REJECTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL FEATURE; CONSENSUS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER ALLOGRAFT FIBROSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; STAINING; ALLOGRAFT; GRAFT REJECTION; IMMUNOLOGY; LIVER TRANSPLANTATION; PATHOLOGY; RESEARCH;

ALLOGRAFTS; GRAFT REJECTION; HUMANS; ISOANTIBODIES; LIVER TRANSPLANTATION; RESEARCH REPORT;

EID: 84978419845     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13909     Document Type: Article

References (205)

1. Pathology BWGoLA. Importance of liver biopsy findings in immunosuppression management: Biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012; 18: 1154–1170.
2. Anonymous. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658–663.
3. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31: 792–799.
4. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229–1242.
5. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563–570.
6. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody- associated arterial lesions. Am J Transplant 2014; 14: 272–283.
7. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013; 32: 1147–1162.
8. Drachenberg CB, Odorico J, Demetris AJ, et al. Banff schema for grading pancreas allograft rejection: Working proposal by a multi-disciplinary international consensus panel. Am J Transplant 2008; 8: 1237–1249.
9. Sánchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011; 140: 51–64.
10. Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489–501.
11. Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006; 43: 1109–1117.
12. Li X, Sun Q, Zhang M, Xie K, Chen J, Liu Z. Capillary dilation and rarefaction are correlated with intracapillary inflammation in antibody-mediated rejection. J Immunol Res 2014; 2014: 582902.
13. Escaned J, Flores A, Garcia-Pavia P, et al. Assessment of microcirculatory remodeling with intracoronary flow velocity and pressure measurements: Validation with endomyocardial sampling in cardiac allografts. Circulation 2009; 120: 1561–1568.
14. Drachenberg CB, Papadimitriou JC. Endothelial injury in renal antibody-mediated allograft rejection: A schematic view based on pathogenesis. Transplantation 2013; 95: 1073–1083.
15. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: Complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant 2014; 19: 33–40.
16. Valenzuela NM, Reed EF. Antibodies in transplantation: The effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol 2013; 1034: 41–70.
17. Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: Current status and novel approaches. Am J Transplant 2014; 14: 255–271.
18. Farkash EA, Colvin RB. Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol 2012; 8: 255–257.
19. de Kort H, Roufosse C, Bajema IM, Drachenberg CB. Pancreas transplantation, antibodies and rejection: Where do we stand? Curr Opin Organ Transplant 2013; 18: 337–344.
20. Demetris AJ, Murase N, Nakamura K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection [Review]. Semin Liver Dis 1992; 12: 51–59.
21. Demetris AJ, Zeevi A, O’Leary JG. ABO-compatible liver allograft antibody-mediated rejection: An update. Curr Opin Organ Transplant 2015; 20: 314–324.
22. O’Leary JG, Demetris AJ, Friedman LS, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014; 14: 779–787.
23. Netto GJ, Watkins DL, Williams JW, et al. Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: The “hepatitis C 3” multi-institutional trial experience. Arch Pathol Lab Med 2006; 130: 1157–1162.
24. Demetris AJ, Ruppert K, Dvorchik I, et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation 2002; 74: 1290–1296.
25. Sebagh M, Blakolmer K, Falissard B, et al. Accuracy of bile duct changes for the diagnosis of chronic liver allograft rejection: Reliability of the 1999 Banff schema. Hepatology 2002; 35: 117–125.
26. Horoldt BS, Burattin M, Gunson BK, et al. Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation? Liver Transpl 2006; 12: 1144–1151.
27. Ormonde DG, de Boer WB, Kierath A, et al. Banff schema for grading liver allograft rejection: Utility in clinical practice. Liver Transpl Surg 1999; 5: 261–268.
28. Abraham SC, Freese DK, Ishitani MB, Krasinskas AM, Wu TT. Significance of central perivenulitis in pediatric liver transplantation. Am J Surg Pathol 2008; 32: 1479–1488.
29. Khettry U, Backer A, Ayata G, Lewis WD, Jenkins RL, Gordon FD. Centrilobular histopathologic changes in liver transplant biopsies. Hum Pathol 2002; 33: 270–276.
30. Sanei MH, Schiano TD, Sempoux C, Fan C, Fiel MI. Acute cellular rejection resulting in sinusoidal obstruction syndrome and ascites postliver transplantation. Transplantation 2011; 92: 1152–1158.
31. Yamada H, Kondou H, Kimura T, et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. Pediatr Transplant 2012; 16: 858–865.
32. Venturi C, Sempoux C, Bueno J, et al. Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children. Am J Transplant 2012; 12: 2986–2996.
33. Sebagh M, Castillo-Rama M, Azoulay D, et al. Histologic findings predictive of a diagnosis of de novo autoimmune hepatitis after liver transplantation in adults. Transplantation 2013; 96: 670–678.
34. Castillo-Rama M, Sebagh M, Sasatomi E, et al. “Plasma cell hepatitis” in liver allografts: Identification and characterization of an IgG4-rich cohort. Am J Transplant 2013; 13: 2966–2977.
35. Fiel MI, Schiano TD. Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation. Curr Opin Organ Transplant 2012; 17: 287–292.
36. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: e1131.
37. Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: Variant of rejection or autoimmune hepatitis? Liver Transpl 2008; 14: 750–755.
38. Fiel MI, Agarwal K, Stanca C, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008; 14: 861–871.
39. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998; 351: 409–413.
40. Ward SC, Schiano TD, Thung SN, Fiel MI. Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: Casecontrol study showing poor outcome and predictive features in the liver explant. Liver Transpl 2009; 15: 1826–1833.
41. Wozniak LJ, Hickey MJ, Venick RS, et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation 2015; 99: 1416–1422.
42. Umemura T, Zen Y, Hamano H, et al. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. J Gastroenterol 2011; 46(Suppl 1): 48–55.
43. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002; 35: 349–356.
44. Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl 2004; 10: 1166–1172.
45. Pongpaibul A, Venick RS, McDiarmid SV, Lassman CR. Histopathology of de novo autoimmune hepatitis. Liver Transpl 2012; 18: 811–818.
46. Trivedi A, Schiano TD, Ward SC, Thung SN, Fiel MI, Levitsky J. C4d is present in portal venules in plasma cell hepatitis and may also be used as a predictor for its development. In: American Association for the Study of Liver Disease, editor. Hepatology. Boston: Wiley-Blackwell, 2014; p. 457A.
47. Aguilera I, Sousa JM, Gavilan F, Gomez L, Alvarez-Marquez A, Nunez-Roldan A. Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. Liver Transpl 2011; 17: 779–788.
48. Aguilera I, Wichmann I, Sousa JM, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001; 126: 535–539.
49. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: Unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007; 7: 955–963.
50. Mendes F, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver Dis 2011; 15: 859–878.
51. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58–72.e4.
52. Hubscher SG. What is the long-term outcome of the liver allograft? J Hepatol 2011; 55: 702–717.
53. Inui A, Sogo T, Komatsu H, Miyakawa H, Fujisawa T. Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation. Liver Transpl 2005; 11: 504–507.
54. Huguet S, Vinh J, Johanet C, et al. Identification by proteomic tool of atypical anti-liver/kidney microsome autoantibodies targets in de novo autoimmune hepatitis after liver transplantation. Ann N Y Acad Sci 2007; 1109: 345–357.
55. Ohe H, Uchida Y, Yoshizawa A, et al. Association of antihuman leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation 2014; 98: 1105–1111.
56. Kerkar N, Yanni G. ‘De novo’ and ‘recurrent’ autoimmune hepatitis after liver transplantation: A comprehensive review. J Autoimmun 2016; 66: 17–24.
57. Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988; 132: 489–502.
58. Gordon RD, Iwatsuki S, Esquivel CO, Tzakis A, Todo S, Starzl TE. Liver transplantation across ABO blood groups. Surgery 1986; 100: 342–348.
59. Rego J, Prevost F, Rumeau JL, et al. Hyperacute rejection after ABO-incompatible orthotopic liver transplantation. Transplant Proc 1987; 19: 4589–4590.
60. Gugenheim J, Samuel D, Fabiani B, et al. Rejection of ABO incompatible liver allografts in man. Transplant Proc 1989; 21(1 Pt 2): 2223–2224.
61. Sanchez-Urdazpal L, Sterioff S, Janes C, Schwerman L, Rosen C, Krom RA. Increased bile duct complications in ABO incompatible liver transplant recipients. Transplant Proc 1991; 23(1 Pt 2): 1440–1441.
62. Doyle HR, Marino IR, Morelli F, et al. Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg 1996; 224: 168–177.
63. Karruppan S, Ericzon BG, Moller E. Relevance of a positive crossmatch in liver transplantation. Transplant Int 1991; 4: 18–25.
64. Takaya S, Bronsther O, Iwaki Y, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400–406.
65. Nikaein A, Backman L, Jennings L, et al. HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation 1994; 58: 786–792.
66. Bathgate AJ, McColl M, Garden OJ, Forsythe JL, Madhavan KK, Hayes PC. The effect of a positive T-lymphocytotoxic crossmatch on hepatic allograft survival and rejection. Liver Transpl Surg 1998; 4: 280–284.
67. Andres GA, Ansell ID, Halgrimson CG, et al. Immunopathological studies of orthotopic human liver allografts. Lancet 1972; 1: 275–280.
68. Gugenheim J, Charpentier B, Gigou M, et al. Delayed rejection of heart allografts after extracorporeal donor-specific liver hemoperfusion. Role of Kupffer cells. Transplantation 1988; 45: 628–632.
69. Gugenheim J, Amorosa L, Gigou M, et al. Specific absorption of lymphocytotoxic alloantibodies by the liver in inbred rats. Transplantation 1990; 50: 309–313.
70. Saidman SL, Duquesnoy RJ, Demetris AJ, et al. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994; 2: 61–67.
71. Eid A, Moore SB, Wiesner RH, De Goey SR, Nielson A, Krom RA. Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver-kidney transplantation across a positive lymphocyte crossmatch. Transplantation 1990; 50: 331–334.
72. Olausson M, Mjörnstedt L, Nordén G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7: 130–136.
73. Hubscher SG. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant 2012; 17: 280–286.
74. Nakamura K, Murase N, Becich MJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993; 142: 1383–1391.
75. Gugenheim J, Houssin D, Tamisier D, et al. Spontaneous longterm survival of liver allografts in inbred rats: Influence of the hepatectomy of the recipient’s own liver. Transplantation 1981; 32: 445–450.
76. Gugenheim J, Le Thai B, Rouger P, et al. Relationship between the liver and lymphocytotoxic alloantibodies in inbred rats. Specific absorption by nonparenchymal liver cells. Transplantation 1988; 45: 474–478.
77. Astarcioglu I, Cursio R, Reynes M, Gugenheim J. Increased risk of antibody-mediated rejection of reduced-size liver allografts. J Surg Res 1999; 87: 258–262.
78. Geissler EK, Graeb C, Tange S, Guba M, Jauch KW, Scherer MN. Effective use of donor MHC class I gene therapy in organ transplantation: Prevention of antibody-mediated hyperacute heart allograft rejection in highly sensitized rat recipients. Hum Gene Ther 2000; 11: 459–469.
79. Demetris AJ, Isse K. Tissue biopsy monitoring of operational tolerance in liver allograft recipients. Curr Opin Organ Transplant 2013; 18: 345–353.
80. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: Characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003; 14: 1336–1348.
81. Page C, Rose M, Yacoub M, Pigott R. Antigenic heterogeneity of vascular endothelium. Am J Pathol 1992; 141: 673–683.
82. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841–847.
83. O’Leary JG, Kaneku H, Jennings LW, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973–980.
84. DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology 2015; 61: 1740–1746.
85. Tuijnman WB, Van Wichen DF, Schuurman HJ. Tissue distribution of human IgG Fc receptors CD16, CD32 and CD64: An immunohistochemical study. APMIS 1993; 101: 319–329.
86. Demetris AJ, Bellamy CO, Gandhi CR, Prost S, Nakanuma Y, Stolz DB. Functional immune anatomy of the liver—as an allograft. Am J Transplant 2016; 16: 1653–1680.
87. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. Curr Pathobiol Rep 2013; 1: 209–214.
88. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984; 38: 287–292.
89. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 1984; 38: 293–298.
90. Lautenschlager I, Taskinen E, Inkinen K, Lehto VP, Virtanen I, Hayry P. Distribution of the major histocompatibility complex antigens on different cellular components of human liver. Cell Immunol 1984; 85: 191–200.
91. Demetris AJ, Lasky S, Thiel DHV, Starzl TE, Whiteside T. Induction of DR/IA antigens in human liver allografts: An immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation 1985; 40: 504–509.
92. Ballardini G, Bianchi FB, Mirakian R, Fallani M, Pisi E, Bottazzo GF. HLA-A, B, C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin Exp Immunol 1987; 70: 35–46.
93. Barbatis C, Kelly P, Greveson J, Heryet A, McGee JO. Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man. J Clin Pathol 1987; 40: 879–884.
94. Steinhoff G, Wonigeit K, Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45: 394–401.
95. Gouw AS, Huitema S, Grond J, et al. Early induction of MHC antigens in human liver grafts. An immunohistologic study. Am J Pathol 1988; 133: 82–94.
96. Steinhoff G, Wonigeit K, Schafers HJ, Haverich A. Sequential analysis of monomorphic and polymorphic major histocompatibility complex antigen expression in human heart allograft biopsy specimens. J Heart Transplant 1989; 8: 360–370.
97. Steinhoff G. Major histocompatibility complex antigens in human liver transplants. J Hepatol 1990; 11: 9–15.
98. Hubscher SG, Adams DH, Elias E. Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection. J Pathol 1990; 162: 165–171.
99. Terada T, Nakanuma Y, Hoso M, Obata H. Expression of HLADR antigen on hepatic vascular endothelial cells in idiopathic portal hypertension. Clin Exp Immunol 1991; 84: 303–307.
100. Terada T, Nakanuma Y, Obata H. HLA-DR expression on the microvasculature of portal tracts in idiopathic portal hypertension. Immunohistochemical characteristics and relation to portal phlebosclerosis. Arch Pathol Lab Med 1991; 115: 993–997.
101. O’Leary JG, Cai J, Freeman R, et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts. Am J Transplant 2016; 16: 603–614.
102. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 1017–1044.
103. Demetris AJ, Ruppert K. Pathologist’s perspective on liver needle biopsy size? J Hepatol 2003; 39: 275–277.
104. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50: 739–749.
105. Bellamy CO. Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: Applications and pitfalls. Liver Transpl 2011; 17: 747–750.
106. Cohen D, Colvin RB, Daha MR, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012; 81: 628–639.
107. Smith RN, Colvin RB. Chronic alloantibody mediated rejection. Semin Immunol 2012; 24: 115–121.
108. Sapir-Pichhadze R, Curran SP, John R, et al. A systematic review of the role of C4d in the diagnosis of acute antibodymediated rejection. Kidney Int 2015; 87: 182–194.
109. Miller DV, Roden AC, Gamez JD, Tazelaar HD. Detection of C4d deposition in cardiac allografts: A comparative study of immunofluorescence and immunoperoxidase methods. Arch Pathol Lab Med 2010; 134: 1679–1684.
110. Ludovico-Martins H, Silva C, Teodoro WR, Martini Filho D, Noronha IL. Analysis of different staining techniques for c4d detection in renal allograft biopsies. Transplant Proc 2009; 41: 862–865.
111. Seemayer CA, Gaspert A, Nickeleit V, Mihatsch MJ. C4d staining of renal allograft biopsies: A comparative analysis of different staining techniques. Nephrol Dial Transplant 2007; 22: 568–576.
112. Troxell ML, Weintraub LA, Higgins JP, Kambham N. Comparison of C4d immunostaining methods in renal allograft biopsies. Clin J Am Soc Nephrol 2006; 1: 583–591.
113. Nadasdy GM, Bott C, Cowden D, Pelletier R, Ferguson R, Nadasdy T. Comparative study for the detection of peritubular capillary C4d deposition in human renal allografts using different methodologies. Hum Pathol 2005; 36: 1178–1185.
114. Chantranuwat C, Qiao JH, Kobashigawa J, Hong L, Shintaku P, Fishbein MC. Immunoperoxidase staining for C4d on paraffinembedded tissue in cardiac allograft endomyocardial biopsies: Comparison to frozen tissue immunofluorescence. Appl Immunohistochem Mol Morphol 2004; 12: 166–171.
115. Bu X, Zheng Z, Yu Y, Zeng L, Jiang Y. Significance of C4d deposition in the diagnosis of rejection after liver transplantation. Transplant Proc 2006; 38: 1418–1421.
116. Dankof A, Schmeding M, Morawietz L, et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005; 447: 87–93.
117. Haga H, Egawa H, Fujimoto Y, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006; 12: 457–464.
118. Jain A, Mohanka R, Orloff M, et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in postliver transplant biopsies. Clin Transplant 2006; 20: 624–633.
119. Krukemeyer MG, Moeller J, Morawietz L, et al. Description of B lymphocytes and plasma cells, complement, and chemokines/ receptors in acute liver allograft rejection. Transplantation 2004; 78: 65–70.
120. Sakashita H, Haga H, Ashihara E, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20: 676–684.
121. Sawada T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005; 19: 110–114.
122. Troxell ML, Higgins JP, Kambham N. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006; 130: 1489–1496.
123. Bouron-Dal Soglio D, Rougemont AL, Herzog D, Soucy G, Alvarez F, Fournet JC. An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases. Hum Pathol 2008; 39: 1103–1110.
124. Schmeding M, Dankof A, Krenn V, et al. C4d in acute rejection after liver transplantation—a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006; 6: 523–530.
125. Silva MA, Mirza DF, Murphy N, et al. Intrahepatic complement activation, sinusoidal endothelial injury, and lactic acidosis are associated with initial poor function of the liver after transplantation. Transplantation 2008; 85: 718–725.
126. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504–1510.
127. O’Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl 2014; 20: 655–663.
128. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357–368.
129. Demetris AJ, Nakamura K, Yagihashi A, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671–681.
130. O’Leary JG, Michelle Shiller S, Bellamy C, et al. Acute liver allograft antibody-mediated rejection: An inter-institutional study of significant histopathological features. Liver Transpl 2014; 20: 1244–1255.
131. Musat AI, Agni RM, Wai PY, et al. The significance of donorspecific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500–510.
132. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: Can C4d stains help in monitoring? Am J Transplant 2012; 12: 171–182.
133. Salah A, Fujimoto M, Yoshizawa A, et al. Application of complement component 4d immunohistochemistry to ABO-compatible and ABO-incompatible liver transplantation. Liver Transpl 2014; 20: 200–209.
134. O’Leary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014; 20: 218–227.
135. Martelius T, Halme L, Arola J, Hockerstedt K, Lautenschlager I. Vascular deposition of complement C4d is increased in liver allografts with chronic rejection. Transpl Immunol 2009; 21: 244–246.
136. Corrêa RR, Machado JR, da Silva MV, et al. The importance of C4d in biopsies of kidney transplant recipients. Clin Dev Immunol 2013; 2013: 678180.
137. Cornell LD. Renal allograft pathology in the sensitized patient. Curr Opin Organ Transplant 2013; 18: 327–336.
138. Raut V, Uemoto S. Management of ABO-incompatible livingdonor liver transplantation: Past and present trends. Surg Today 2011; 41: 317–322.
139. Haga H, Egawa H, Shirase T, et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl 2004; 10: 16–27.
140. Manez R, Kelly RH, Kobayashi M, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: Studies toward further defining their significance. Hepatology 1995; 21: 1345–1352.
141. O’Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant 2013; 18: 279–284.
142. Al-Sibae MR, Koffron AJ, Raofi V. Does a positive pretransplant crossmatch affect long-term outcome in liver transplantation? Transplantation 2011; 91: 261–262.
143. Chan KM, Lee CS, Wu TJ, Lee CF, Chen TC, Lee WC. Clinical perspective of acute humoral rejection after blood typecompatible liver transplantation. Transplantation 2011; 91: e29–e30.
144. Tambur AR, Herrera ND, Haarberg KM, et al. Assessing antibody strength: Comparison of MFI, C1q, and titer information. Am J Transplant 2015; 15: 2421–2430.
145. Starzl TE, Demetris AJ, Todo S. Evidence of hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transpl 1989; 3: 37–45.
146. Hori T, Egawa H, Takada Y, et al. Fatal impact of lymphocyte cross-matching upon humoral rejection after adult living related liver transplantation. Transpl Int 2010; 23: 338–340.
147. Fung J, Griffin M, Duquesnoy R, Shaw B, Starzl T. Successful sequential liver-kidney transplantation in a patient with performed lymphocytotoxic antibodies. Transpl Proc 1987; 19(1 Pt 1): 767–768.
148. O’Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954–960.
149. Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014; 14: 867–875.
150. Colvin RB. Dimensions of antibody-mediated rejection. Am J Transplant 2010; 10: 1509–1510.
151. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046–1056.
152. Martin T, Schwartz J, Demetris A, Comstock J, Lowichik A, Book L. Plasmapheresis treatment of antibody-mediated rejection in an A2 donor to O pediatric liver transplant recipient. Pediatr Transplant 2011; 15: E15–E18.
153. Egawa H, Uemoto S, Inomata Y, et al. Biliary complications in pediatric living related liver transplantation. Surgery 1998; 124: 901–910.
154. Sebagh M, Farges O, Kalil A, Samuel D, Bismuth H, Reynes M. Sclerosing cholangitis following human orthotopic liver transplantation. Am J Surg Pathol 1995; 19: 81–90.
155. Kakizoe S, Yanaga K, Starzl TE, Demetris AJ. Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: Considerations of preservation and early immunological injury. Hepatology 1990; 11: 932–941.
156. Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022–3029.
157. Iacob S, Cicinnati VR, Dechêne A, et al. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver Int 2012; 32: 1253–1261.
158. Song SH, Kim MS, Lee JJ, et al. Effect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients. Ann Surg Treat Res 2015; 88: 100–105.
159. Rostron A, Carter V, Mutunga M, et al. A case of acute humoral rejection in liver transplantation: Successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int 2005; 18: 1298–1301.
160. Aoki T, Sugawara Y, Takahashi M, et al. Living donor liver transplantation using sensitized lymphocytotoxic crossmatch positive graft. J Gastroenterol 2012; 47: 486–488.
161. Kheradmand T, Anthony TL, Harland RC, et al. Antibodymediated rejection in ABO compatible husband to wife living donor liver transplant and review of the literature. Hum Immunol 2014; 75: 578–583.
162. Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V. Sinusoidal C4d deposits in liver allografts indicate an antibodymediated response: Diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012; 18: 641–658.
163. Kaneku H, O’Leary JG, Banuelos N, et al. De novo donorspecific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541–1548.
164. Kaneku H, O’Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984–992.
165. O’Leary J, Kaneku H, Banuelos N, Jennings L, Klintmalm G, Terasaki P. Impact of IgG3 subclass and C1q-fixing donor specific antibodies on rejection and survival in liver transplantation. Am J Transplant 2015; 15: 1003–1013.
166. Feng S, Demetris AJ, Spain KM, et al. Five year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R. Hepatology 2016. doi: 10.1002/hep.28681. [Epub ahead of print]
167. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333–1342.
168. Iacob S, Cicinnati VR, Lindemann M, et al. Donor-specific anti- HLA antibodies and endothelial C4d deposition-association with chronic liver allograft failure. Transplantation 2015; 99: 1869–1875.
169. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283–293.
170. Solez K, Colvin RB, Racusen LC, et al. Banff ‘05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 2007; 7: 518–526.
171. Shimizu A, Ishii E, Kuwahara N, et al. Chronic antibody-mediated responses may mediate chronic rejection in rat orthotopic liver transplantation. Transplant Proc 2013; 45: 1743–1747.
172. Wan R, Ying W, Zeng L, Deng X, Chen H, Gao L. Antibodymediated response in rat liver chronic rejection. Transplant Proc 2011; 43: 1976–1979.
173. Donaldson PT, Alexander GJ, O’Grady J, et al. Evidence for an immune response to HLA class I antigens in the vanishing-bile duct syndrome after liver transplantation. Lancet 1987; 1: 945–951.
174. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation 1993; 56: 69–75.
175. Donaldson PT, Thomson LJ, Heads A, et al. IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation. An assessment by cytotoxicity and flow cytometry. Transplantation 1995; 60: 1016–1023.
176. Grabhorn E, Binder TM, Obrecht D, et al. Long-term clinical relevance of de novo donor-specific antibodies after pediatric liver transplantation. Transplantation 2015; 99: 1876–1881.
177. Markiewicz-Kijewska M, Kaliciński P, Kluge P, et al. Immunological factors and liver fibrosis in pediatric liver transplant recipients. Ann Transplant 2015; 20: 279–284.
178. Batts KP, Moore SB, Perkins JD, Wiesner RH, Grambsch PM, Krom RA. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45: 376–379.
179. Kosola S, Lampela H, Jalanko H, et al. Low-dose steroids associated with milder histological changes after pediatric liver transplantation. Liver Transpl 2013; 19: 145–154.
180. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009; 87: 606–614.
181. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007; 17: 94–97.
182. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574–582.
183. Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation 2012; 93: 1173–1178.
184. Demetris AJ, Lunz JG 3rd, Randhawa P, Wu T, Nalesnik M, Thomson AW. Monitoring of human liver and kidney allograft tolerance: A tissue/histopathology perspective. Transpl Int 2009; 22: 120–141.
185. Benitez C, Londono MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58: 1824–1835.
186. Egawa H, Miyagawa-Hayashino A, Haga H, et al. Noninflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal. Hepatol Res 2012; 42: 895–903.
187. Li Y, Lu L, Qian S, Fung JJ, Lin F. Hepatic stellate cells directly inhibit B cells via programmed death-ligand 1. J Immunol 2016; 196: 1617–1625.
188. Song GW, Lee SG, Hwang S, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. Am J Transplant 2016; 16: 157–170.
189. Kim P, Demetris A, O’Leary J. Prevention and treatment of liver allograft antibody mediated rejection and the role of the “2-hit hypothesis”. Curr Opin Organ Transplant 2016; 21: 209–218.
190. Musat AI, Pigott CM, Ellis TM, et al. Pretransplant donorspecific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation. Liver Transpl 2013; 19: 1132–1141.
191. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554–562.
192. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526–2531.
193. Kamar N, Lavayssiere L, Muscari F, et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15: 3426–3430.
194. Schadde E, d’Alessandro AM, Musat AI, Torrealba JR, Knechtle SJ. Donor-specific HLA-antibody-mediated humoral rejection in a liver transplant recipient fully reversed with plasmapheresis and immunoglobulin. Clin Transpl 2006; 479–482.
195. Wilson CH, Agarwal K, Carter V, et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006; 82: 988–989.
196. Del Bello A, Congy-Jolivet N, Danjoux M, et al. De novo donorspecific anti-HLA antibodies mediated rejection in livertransplant patients. Transpl Int 2015; 28: 1371–1382.
197. O’Leary JG, Samaniego M, Barrio MC, et al. The influence of immunosuppressive agents on the risk of de novo donorspecific HLA antibody production in solid organ transplant recipients. Transplantation 2016; 100: 39–53.
198. Wong T, Nouri-Aria KT, Devlin J, Portmann B, Williams R. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 1998; 28: 443–449.
199. Feng S, Bucuvalas J, Demetris A, et al. Deceased donor and class II donor specific antibody predict interface activity while increased age at time of biopsy predicts fibrosis in long-term pediatric liver allografts with normal liver tests: iWITH clinical trial [abstract]. Am J Transplant 2015; 15 (Suppl 3).
200. Bohne F, Martinez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Investig 2012; 122: 368–382.
201. Taubert R, Danger R, Londoño MC, et al. Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are down-regulated. Am J Transplant 2016; 16: 1285–1293.
202. Dragun D, Catar R, Philippe A. Non-HLA antibodies in solid organ transplantation: Recent concepts and clinical relevance. Curr Opin Organ Transplant 2013; 18: 430–435.
203. Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody mediated rejection. Hum Immunol 2012; 73: 1226–1232.
204. Sellares J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody- mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971–983.
205. Wu KY, Budde K, Schmidt D, Neumayer HH, Rudolph B. Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations. Clin Transplant 2014; 28: 410–418.